Please check your internet connection and try again.
# L-Ornithine L-Aspartate (Hepamerz)
## Overview
L-Ornithine L-Aspartate (LOLA) is an amino acid derivative used primarily in the management of hyperammonemia associated with liver disease.
## Primary Indications
* Hepatic encephalopathy (HE)
## Adult Dosing
* **Oral:** Typically 9-18 grams per day, divided into 3 doses.
* **Intravenous (IV):** 5-20 grams per day, administered as a continuous infusion or intermittently. Specific dosing and duration depend on the severity of HE and institutional protocols.
## Pediatric Dosing
* Dosing in pediatric patients is not well-established and requires careful consideration based on individual clinical assessment, the severity of liver disease, and local protocols. Limited data suggests doses may range from 100-500 mg/kg/day divided into multiple doses.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment, as the drug is metabolized by the liver and its metabolites are excreted by the kidneys. However, caution is advised in severe organ dysfunction.
## Contraindications
* Hypersensitivity to L-Ornithine L-Aspartate.
* Severe kidney disease (potential for accumulation of amino acids).
## Adverse Effects
* Gastrointestinal disturbances: Nausea, vomiting, diarrhea, abdominal pain.
* Rarely: Allergic reactions.
## Key Drug Interactions
* Generally, significant drug interactions are not well-documented. However, it is prudent to consider potential additive effects with other medications affecting ammonia levels or gastrointestinal motility.
## Monitoring
* Serum ammonia levels (though correlation with clinical response can be variable).
* Clinical signs and symptoms of hepatic encephalopathy.
* Renal and liver function.
## Clinical Pearls
* LOLA works by promoting the detoxification of ammonia in the liver and peripheral tissues. Ornithine is involved in the urea cycle, and aspartate provides nitrogen for glutamine synthesis, helping to reduce ammonia levels.
* Oral administration may be more effective for chronic management, while IV administration is typically used in acute settings or for severe HE.
* The effectiveness of LOLA can vary, and it is often used as an adjunct to other therapies for HE.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive guidance. Drug information can change, and individual patient factors must be considered.
